CN102802668A - 包含至少一种肾上腺素能化合物的稳定化组合物 - Google Patents

包含至少一种肾上腺素能化合物的稳定化组合物 Download PDF

Info

Publication number
CN102802668A
CN102802668A CN201080024241XA CN201080024241A CN102802668A CN 102802668 A CN102802668 A CN 102802668A CN 201080024241X A CN201080024241X A CN 201080024241XA CN 201080024241 A CN201080024241 A CN 201080024241A CN 102802668 A CN102802668 A CN 102802668A
Authority
CN
China
Prior art keywords
antioxidant
range
adrenergic compound
pharmaceutical composition
sulfite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201080024241XA
Other languages
English (en)
Chinese (zh)
Inventor
A·J·柏利
K·麦克唐纳
P·波蒂厄斯
S·亨德里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALK Abello AS
Original Assignee
ALK AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALK AG filed Critical ALK AG
Priority to CN201610726131.7A priority Critical patent/CN106109397A/zh
Publication of CN102802668A publication Critical patent/CN102802668A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201080024241XA 2009-06-04 2010-06-03 包含至少一种肾上腺素能化合物的稳定化组合物 Pending CN102802668A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610726131.7A CN106109397A (zh) 2009-06-04 2010-06-03 包含至少一种肾上腺素能化合物的稳定化组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18406609P 2009-06-04 2009-06-04
DKPA200900705 2009-06-04
US61/184,066 2009-06-04
DKPA200900705 2009-06-04
PCT/EP2010/057772 WO2010139752A2 (en) 2009-06-04 2010-06-03 Stabilised composition comprising at least one adrenergic compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610726131.7A Division CN106109397A (zh) 2009-06-04 2010-06-03 包含至少一种肾上腺素能化合物的稳定化组合物

Publications (1)

Publication Number Publication Date
CN102802668A true CN102802668A (zh) 2012-11-28

Family

ID=41364279

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201080024241XA Pending CN102802668A (zh) 2009-06-04 2010-06-03 包含至少一种肾上腺素能化合物的稳定化组合物
CN201610726131.7A Pending CN106109397A (zh) 2009-06-04 2010-06-03 包含至少一种肾上腺素能化合物的稳定化组合物
CN201080024234XA Pending CN102497882A (zh) 2009-06-04 2010-06-03 包含至少一种肾上腺素能化合物的稳定化组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201610726131.7A Pending CN106109397A (zh) 2009-06-04 2010-06-03 包含至少一种肾上腺素能化合物的稳定化组合物
CN201080024234XA Pending CN102497882A (zh) 2009-06-04 2010-06-03 包含至少一种肾上腺素能化合物的稳定化组合物

Country Status (15)

Country Link
US (1) US9155694B2 (cg-RX-API-DMAC7.html)
EP (2) EP2437782B1 (cg-RX-API-DMAC7.html)
JP (2) JP2012528830A (cg-RX-API-DMAC7.html)
KR (2) KR20120028344A (cg-RX-API-DMAC7.html)
CN (3) CN102802668A (cg-RX-API-DMAC7.html)
AU (2) AU2010255748B2 (cg-RX-API-DMAC7.html)
BR (2) BRPI1013019A2 (cg-RX-API-DMAC7.html)
CA (2) CA2764051A1 (cg-RX-API-DMAC7.html)
DK (2) DK2437781T3 (cg-RX-API-DMAC7.html)
ES (2) ES2432164T3 (cg-RX-API-DMAC7.html)
MX (2) MX2011012732A (cg-RX-API-DMAC7.html)
PT (2) PT2437782E (cg-RX-API-DMAC7.html)
RU (2) RU2527680C2 (cg-RX-API-DMAC7.html)
SI (2) SI2437782T1 (cg-RX-API-DMAC7.html)
WO (2) WO2010139752A2 (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103520096A (zh) * 2013-10-25 2014-01-22 成都晶博生物科技有限责任公司 一种硫酸特布他林注射液的生产工艺
CN106061253A (zh) * 2013-12-18 2016-10-26 温德加普医疗股份有限公司 药物混合和递送系统及方法
US11246842B2 (en) 2014-12-18 2022-02-15 Windgap Medical, Inc. Method and compositions for dissolving or solubilizing therapeutic agents
CN114286669A (zh) * 2019-08-08 2022-04-05 太阳医药工业有限公司 去甲肾上腺素的输注剂型
US12239822B2 (en) 2013-03-15 2025-03-04 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8628805B2 (en) * 2009-06-04 2014-01-14 Alk Ag Stabilized composition comprising at least one adrenergic compound
CN102525894A (zh) * 2012-01-04 2012-07-04 上海禾丰制药有限公司 盐酸异丙肾上腺素注射液及其制剂工艺
CN102525893B (zh) * 2012-01-04 2013-11-20 上海禾丰制药有限公司 盐酸去氧肾上腺素注射液及其制剂工艺
AU2013328393A1 (en) * 2012-10-08 2015-04-09 Wockhardt Limited Stable injectable pharmaceutical composition of epinephrine or salts thereof
TWI780236B (zh) * 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
BR112016007328A2 (pt) 2013-10-03 2017-08-01 Imprimis Pharmaceuticals Inc composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas
US12702651B2 (en) 2013-10-03 2026-08-11 Harrow Ip, Llc Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイSanofi インスリンアナログおよび/またはインスリン誘導体の安定化された医薬製剤
UY35988A (es) * 2014-02-27 2015-09-30 Sint Sa Proceso para la producción de una solución inyectable de noradrenalina de baja concentración
PL2990031T3 (pl) 2014-08-28 2020-05-18 Sun Pharmaceutical Industries Ltd Pozajelitowa postać norepinefryny
US20170189352A1 (en) 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
US9119876B1 (en) * 2015-03-13 2015-09-01 Par Pharmaceutical, Inc. Epinephrine formulations
US10039710B2 (en) * 2015-09-18 2018-08-07 Insys Development Company, Inc. Epinephrine spray formulations
US11517525B2 (en) * 2015-09-18 2022-12-06 Hikma Pharmaceuticals Usa Inc. Epinephrine spray formulations
WO2018039420A1 (en) * 2016-08-25 2018-03-01 Imprimis Pharmaceuticals, Inc. Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
RU2635759C1 (ru) * 2016-09-13 2017-11-15 Интеллег Сосьете Анониме Фармацевтическая композиция для парентерального введения и способ ее получения
US10835503B2 (en) 2017-01-13 2020-11-17 Teva Pharmaceuticals Usa, Inc. Pre-filled syringe
WO2018140894A1 (en) 2017-01-30 2018-08-02 Nevakar, Inc Norepinephrine compositions and methods therefor
US20250177328A1 (en) 2017-01-30 2025-06-05 Nevakar Injectables Inc. Norepinephrine compositions and methods therefor
EP3612173B1 (en) * 2017-04-17 2023-10-11 Hikma Pharmaceuticals USA Inc. Epinephrine spray formulations
EP3687475A4 (en) * 2017-09-26 2021-07-28 YS Pharmtech STABILIZATION OF EPINEPHRIN FORMULATIONS
JP2020536926A (ja) 2017-10-10 2020-12-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung L−エピネフリンの安定化注射用医薬用組成物
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CA3093725C (en) 2018-03-23 2021-08-24 Nevakar Inc. Epinephrine compositions and containers
US10952962B1 (en) 2018-04-11 2021-03-23 QuVa Pharma, Inc. Ready to use liquid formulation
CA3096684A1 (en) 2018-04-11 2019-10-17 Travis A. Leeah Ready-to-use liquid reck formulation
US10478406B2 (en) 2019-03-18 2019-11-19 HARC Therapeutics AG High-pH solid-state epinephrine formulation
CN116474218A (zh) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
USD1004518S1 (en) 2019-09-09 2023-11-14 Brunswick Corporation Railing for a marine vessel
CA3174640A1 (en) * 2020-03-06 2021-09-10 Baxter International Inc. Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation
USD984953S1 (en) 2021-05-03 2023-05-02 Brunswick Corporation Safely railing having buoy holder
AU2021203856B2 (en) * 2021-06-10 2023-03-09 Animal Ethics Pty Ltd Topical anaesthetic composition having improved vasoconstrictor stability
EP4547232A4 (en) * 2022-08-27 2025-10-08 Biophore India Pharmaceuticals Pvt Ltd TRIENTINE LIQUID DOSAGE FORMS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3149035A (en) * 1961-04-28 1964-09-15 Univ California Stabilization of epinephrine
JPH06298640A (ja) * 1993-04-15 1994-10-25 Nippon Seiyaku Kk 静脈注射剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB425678A (en) 1933-06-15 1935-03-15 Novocol Chemical Mfg Co Inc Improvements relating to anesthetics for hypodermic injection
US2047144A (en) * 1934-03-26 1936-07-07 Lilly Co Eli Stabilized epinephrine-type compound, and process of stabilizing it
US2382546A (en) * 1941-11-03 1945-08-14 Curtis David Anesthetic solutions
US3419035A (en) * 1965-05-25 1968-12-31 Badger Meter Mfg Co Air elimination device for liquid transport system
CA981182A (en) 1972-01-07 1976-01-06 Walter A. Borisenok Stabilization of 1-epinephrine in local anesthetic solutions with a combination of three antioxidants
US3966905A (en) 1973-05-29 1976-06-29 Barnes-Hind Pharmaceuticals, Inc. Stabilized catechol amine solutions
DD150694A1 (de) 1980-04-16 1981-09-16 Gisela Raether Verfahren zur stabilisierung von pharmazeutischen praeparaten mit oxidationsempfindlichen bestandteilen
US4734438A (en) 1983-04-26 1988-03-29 Macri Frank J Norepinephrine potentiated compositions and method of use
WO1994013274A1 (en) 1992-12-10 1994-06-23 Abbott Laboratories Stabilized catecholamine solutions
US6077545A (en) 1995-10-30 2000-06-20 Matrix Pharmaceuticals, Inc. Process and composition for therapeutic cisplatin (CDDP)
JP2001505197A (ja) 1996-11-14 2001-04-17 アルザ・コーポレーション リドカイン及びエピネフリンの電気的補助投与のための製剤
CA2265767C (en) 1997-07-11 2007-12-04 Nobuyuki Hanamura Stable pharmaceutical composition including 4,5-epoxy-morphinan derivative
JP4393641B2 (ja) 1998-11-26 2010-01-06 久光製薬株式会社 イオントフォレーシス用粘着ゲル組成物及びその装置
EP1326642A2 (en) 2000-09-29 2003-07-16 Board of Trustees operating Michigan State University Catecholamine pharmaceutical compositions and methods
CN100522998C (zh) 2003-10-01 2009-08-05 协和发酵麒麟株式会社 抗体的稳定化方法和被稳定的溶液状抗体制剂
UA71839C2 (uk) 2003-12-30 2007-06-25 Товариство З Обмеженою Відповідальністю "Фарм-Стом" Фармацевтична композиція на основі артикаїну та епінефрину
US20050228336A1 (en) 2004-04-07 2005-10-13 Preston Keusch Electrically assisted lidocaine and epinephrine delivery device having extended shelf-stability
US20060129122A1 (en) 2004-12-06 2006-06-15 Wyrick Ronald E Method and apparatus for delivering epinephrine
NZ571537A (en) 2006-04-03 2012-06-29 Nutramax Lab Inc Stabilized pentosan polysulfate (PPS) formulations and methods of analayzing them
US20070249727A1 (en) * 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US20080269347A1 (en) 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations
US8628805B2 (en) 2009-06-04 2014-01-14 Alk Ag Stabilized composition comprising at least one adrenergic compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3149035A (en) * 1961-04-28 1964-09-15 Univ California Stabilization of epinephrine
JPH06298640A (ja) * 1993-04-15 1994-10-25 Nippon Seiyaku Kk 静脈注射剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
H.WOLLMANN ET AL.: "Examination of the efficiency of stabilizing agents in Epinephrine model solutions", 《PHARMACY》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12239822B2 (en) 2013-03-15 2025-03-04 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods
CN103520096A (zh) * 2013-10-25 2014-01-22 成都晶博生物科技有限责任公司 一种硫酸特布他林注射液的生产工艺
CN103520096B (zh) * 2013-10-25 2015-02-25 成都晶博生物科技有限责任公司 一种硫酸特布他林注射液的生产工艺
CN106061253A (zh) * 2013-12-18 2016-10-26 温德加普医疗股份有限公司 药物混合和递送系统及方法
CN113230486A (zh) * 2013-12-18 2021-08-10 温德加普医疗股份有限公司 药物混合和递送系统及方法
US12239823B2 (en) 2013-12-18 2025-03-04 Windgap Medical, Inc. Drug mixing and delivery system and method
US11246842B2 (en) 2014-12-18 2022-02-15 Windgap Medical, Inc. Method and compositions for dissolving or solubilizing therapeutic agents
CN114286669A (zh) * 2019-08-08 2022-04-05 太阳医药工业有限公司 去甲肾上腺素的输注剂型

Also Published As

Publication number Publication date
WO2010139752A2 (en) 2010-12-09
AU2010255748A1 (en) 2011-12-08
AU2010255747B2 (en) 2014-03-13
ES2432241T3 (es) 2013-12-02
WO2010139751A3 (en) 2011-04-07
CA2764050C (en) 2017-02-28
RU2011153410A (ru) 2013-07-20
JP2012528831A (ja) 2012-11-15
CA2764051A1 (en) 2010-12-09
SI2437781T1 (sl) 2013-12-31
AU2010255748B2 (en) 2014-03-13
CN102497882A (zh) 2012-06-13
MX2011012735A (es) 2012-02-28
RU2527337C2 (ru) 2014-08-27
CN106109397A (zh) 2016-11-16
RU2527680C2 (ru) 2014-09-10
WO2010139752A3 (en) 2011-04-07
ES2432164T3 (es) 2013-12-02
DK2437782T3 (da) 2013-10-28
EP2437781A2 (en) 2012-04-11
EP2437782B1 (en) 2013-07-24
RU2011153403A (ru) 2013-07-20
KR20120028344A (ko) 2012-03-22
BRPI1013019A2 (pt) 2016-03-29
PT2437781E (pt) 2013-10-30
SI2437782T1 (sl) 2013-12-31
MX2011012732A (es) 2012-02-28
AU2010255747A1 (en) 2012-02-02
DK2437781T3 (da) 2013-10-21
WO2010139751A2 (en) 2010-12-09
KR20120044309A (ko) 2012-05-07
RU2527337C9 (ru) 2014-12-27
US20120129944A1 (en) 2012-05-24
EP2437781B1 (en) 2013-07-24
BRPI1011074A2 (pt) 2016-04-12
PT2437782E (pt) 2013-10-30
JP6087145B2 (ja) 2017-03-01
CA2764050A1 (en) 2010-12-09
EP2437782A2 (en) 2012-04-11
JP2012528830A (ja) 2012-11-15
US9155694B2 (en) 2015-10-13

Similar Documents

Publication Publication Date Title
US9155694B2 (en) Stabilized composition comprising at least one adrenergic compound
US8628805B2 (en) Stabilized composition comprising at least one adrenergic compound
US12310930B2 (en) Stabilization of epinephrine formulations
US20190240337A1 (en) Epinephrine formulations for medicinal products
US11925608B2 (en) Stabilization of epinephrine formulations
WO2009098716A2 (en) Stable pharmaceutical aqueous compositions
HK1162976A1 (en) Stabilised composition comprising at least one adrenergic compound
HK1162976B (en) Stabilised composition comprising at least one adrenergic compound
HK1162975B (en) Stabilised composition comprising at least one adrenergic compound
KR20250126760A (ko) 위마비를 치료하기 위한 신규한 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160405

Address after: Holm Hess, Denmark

Applicant after: Alk Abello AS

Address before: The Swiss Cortese,

Applicant before: ALK AG

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20121128